FDA flags vision loss risk with GLP-1 drugs

Analysis found higher rates of a rare optic nerve condition, prompting new warnings across the drug class.

By
Mouj Hijazi
November 10, 2026
2 min

MDSpire News

At a Glance

Category	Detail
Condition	Potential association between GLP-1 receptor agonists and nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, painless, potentially permanent vision loss.
Key Mechanisms	The FDA's animal data review did not identify a mechanism explaining the potential increased risk.
Target Population	People using GLP-1 receptor agonists for type 2 diabetes or weight management; the FDA Sentinel cohort study included adults with type 2 diabetes initiating GLP-1 RAs, SGLT2 inhibitors, or DPP4 inhibitors.
Care Setting	Medication safety and prescribing, with prompt ophthalmologic evaluation for suspected NAION.

Key Highlights

The FDA directed manufacturers to add NAION risk information to the Warnings and Precautions section of prescribing information for all marketed GLP-1 RAs.
In a meta-analysis of 126 randomized trials involving 134,253 patients, the FDA identified 15 probable NAION cases: 10 among GLP-1 RA recipients and 5 among comparator recipients; all comparator cases occurred in the placebo group.
In the meta-analysis, NAION incidence was 6.4 cases per 100,000 person-years with GLP-1 RAs and 3.8 with comparators.
In the Sentinel cohort, incidence ranged from 30 to 32 cases per 100,000 person-years with GLP-1 RAs, compared with 31 for SGLT2 inhibitors and 26 for DPP4 inhibitors; risk was statistically significantly higher versus DPP4 inhibitors, but not versus SGLT2 inhibitors.
NAION cases have been reported with all currently marketed GLP-1 RAs; the FDA noted that postmarketing reports are difficult to interpret because NAION risk factors overlap with conditions common among GLP-1 RA users.

Guideline-Based Recommendations

Diagnosis

Consider suspected NAION when a patient reports sudden, painless visual changes.

Management

Instruct patients to immediately report sudden, painless visual changes.
Promptly refer suspected NAION cases for ophthalmologic evaluation.
Consider discontinuing a GLP-1 RA in patients who develop NAION unless treatment benefits clearly outweigh the risks.

Monitoring & Follow-up

Advise patients taking GLP-1 RAs to report sudden, painless visual changes immediately.

Risks

NAION is rare and can cause sudden, painless, potentially permanent vision loss.
The FDA identified a potential increased risk; its Sentinel analysis found a statistically significant increase compared with DPP4 inhibitors, but not compared with SGLT2 inhibitors.
Diabetes, hypertension, and sleep apnea are among the risk factors that complicate interpretation of postmarketing reports.

Patient & Prescribing Data

GLP-1 RAs covered include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound), used for type 2 diabetes and weight management.

The FDA recommends counseling patients to report sudden, painless visual changes immediately. If NAION develops, consider GLP-1 RA discontinuation unless treatment benefits clearly outweigh the risks.

Clinical Best Practices

Discuss the FDA-required NAION warning with patients prescribed GLP-1 RAs.
Tell patients to report sudden, painless visual changes immediately.
Arrange prompt ophthalmologic evaluation when NAION is suspected.
If NAION develops, weigh the benefits of continued GLP-1 RA treatment against the risks when considering discontinuation.